Overall, the individual risk of cardiac arrhythmias secondary to these antimicrobials is minimal; yet, if combined with a genetic propensity to poor metabolism of CYP3A4-inducing medications and co-administration with other CYP potentiators, the risk may be magnified, although the clinical impact of this is unknown. Here, CYP3A4 is linked to cardiac rhythm disease.